Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27616882 | 0.81 | PTGS2 (0.50) | PTGS2 | |
| SCHEMBL1645197 | 0.79 | PTGS2 (0.49) | SLC6A4SLC6A2SLC6A3PTGS2 | |
| SCHEMBL8876620 | 0.78 | PTGS2 (0.51) | PTGS2 | |
| SCHEMBL3016133 | 0.75 | PTGS2 (0.46) | PTGS2 | |
| SCHEMBL9959538 | 0.74 | CHRM2 (0.54) | SLC6A4SLC6A3PTGS2NPY1R | |
| SCHEMBL8533948 | 0.74 | SLC6A4 (0.79) | SLC6A4SLC6A2SLC6A3LMNASMN1; SMN2 | |
| SCHEMBL16846614 | 0.74 | PTGS2 (0.49) | SLC6A4SLC6A2SLC6A3LMNAPTGS2 | |
| SCHEMBL9727526 | 0.74 | APOBEC3G (0.53) | SLC6A4LMNAPTGS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL8672850 | 0.73 | PTGS2 (0.59) | LMNAPTGS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL6065023 | 0.73 | CYSLTR2 (0.56) | PTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893575-B1 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H LUNDBECK AS (DK) | 2017-01-11 | — | — | EP | disclosed |
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7737171-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7678800-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence | H. LUNDBECK A/S (DK) | 2010-03-16 | — | — | US | disclosed |
| US-7652150-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs | H. LUNDBECK A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-7629473-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2009-12-08 | — | — | US | disclosed |
| US-20090192213-A1 | Benzo[b]furane And Benzo[b]thiophene Derivatives | H. LUNDBECK A/S (DK) | 2009-07-30 | — | — | US | disclosed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | disclosed |
| US-7534791-B2 | Benzo[b]furane and benzo[b]thiophene derivatives | H. LUNDBECK A/S (DK) | 2009-05-19 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1220831-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Products Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0859757-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | Farmak A.S. (CZ) | 1998-08-26 | — | — | EP | disclosed |
| EP-0859757-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | Farmak A.S. (CZ) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017325-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | FARMAK A.S. (CZ) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017325-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | FARMAK A.S. (CZ) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | SLC6A4, SLC18A2, SLC6A2 | SLC6A4 1/4885SLC6A2 3/4885SLC6A3 6/4885 |
| US-20090192213-A1 | Benzo[b]furane And Benzo[b]thiophene Derivatives | CYP1B1, TBCB, CYP4B1 | SLC6A4 692/4885SLC6A2 1500/4885SLC6A3 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.